Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III trial evaluating the efficacy of XEN901 for the treatment of pediatric patients with SCN8A epileptic encephalopathy (SCN8A-EE)

Trial Profile

A Phase II/III trial evaluating the efficacy of XEN901 for the treatment of pediatric patients with SCN8A epileptic encephalopathy (SCN8A-EE)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XEN 901 (Primary)
  • Indications Encephalopathy; Epilepsy
  • Focus Therapeutic Use
  • Sponsors Xenon Pharmaceuticals
  • Most Recent Events

    • 02 Dec 2019 According to a Xenon Pharmaceuticals media release, the company anticipates filing an IND application with the FDA in the middle of 2020 in order to start this study.
    • 05 Nov 2019 According to a Xenon Pharmaceuticals media release, the company expects to initiate this trial in 2020.
    • 05 Jun 2019 According to a Xenon Pharmaceuticals media release, the company will submit an IND to start this proposed trial. More details about the final trial design, criteria and endpoints will be disclosed over the coming months.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top